Dr. Mark Pimentel is an Associate Professor of Medicine and of Gastroenterology at Cedars-Sinai, where he heads the Pimentel Lab and is also the executive director of the Medically Associated Science and Technology (MAST) program at Cedars-Sinai, which focuses on the study of the gut microbiome to develop effective diagnostic tools and therapies. Dr. Pimentel is also a Professor of Medicine at the Geffen School of Medicine, University of California, Los Angeles (UCLA). He earned his medical degree and his BSc (Med) from the University of Manitoba Health Sciences Center, where he also completed a residency in internal medicine. His medical training also includes a fellowship in gastroenterology at Cedars-Sinai. As a physician and researcher, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational, and clinical investigations of irritable bowel syndrome (IBS) and the relationship between gut flora composition and human disease. This research led to the first blood test for IBS, ibs-smart™, which measures the levels of two validated IBS biomarkers, anti-CdtB and anti-vinculin. Dr. Pimentel has published over 150 original manuscripts. He is a diplomate of the American Board of Internal Medicine (Gastroenterology), a fellow of the Royal College of Physicians and Surgeons of Canada (FRCP), and a member of the American Gastroenterological Association, the American College of Gastroenterology, and the American Neurogastroenterology and Motility Society.